StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen NEUPOGEN (filgrastim by Quarter

NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)

QuarterlyAnnual

Amgen NEUPOGEN (filgrastim: $12M in Q4 2022, down 25.0% from a year earlier. That is the lowest of the 24 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2022
12
Period ended Dec 31, 2022
Change on a year earlier
-25.0%
16 in Q4 2021
History
24 quarters
Since Q1 2017
Sources
22
Documents cited below

Where the Q4 2022 figure comes from

“|| NEUPOGEN ® | 22 | 12 | 34 | 31 | 10%”

Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202212-25.0%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202214-30.0%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202216+6.7%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202215-6.2%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 202116-15.8%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 202120-4.8%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202115-28.6%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202116-20.0%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 202019-9.5%Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 202021-4.5%Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 202021+5.0%Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 202020-13.0%Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗
Q4 2019Dec 31, 201921-34.4%Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
Q3 2019Sep 30, 201922-33.3%Form 8-K (amgn-2019930xq3exhibit.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 201920-48.7%Form 8-K (amgn-2019630xq2exhibit991f.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 201923-39.5%Form 8-K (amgn-2019331xq1exhibit991f.htm, filed 2019-04-30) ↗

Cite this data

StockData. (2026). Amgen NEUPOGEN (filgrastim ($M), quarterly Q1 2017–Q4 2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neupogen-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.